Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability Growth in 20254Q 2024 Total Revenues of $747 million (+16% Y/Y and +21% at Constant Currency Y/Y); FY 2024 Total Revenues of $2.85 billion (+18% Y/Y and +22% at Constant Currency Y/Y)Conference Call and Webcast Scheduled Today at 4:30 p.m. ETSAN RAFAEL, Calif., Feb. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced fina ...

BioMarin Pharmaceutical (BMRN) is scheduled to report fourth-quarter and full-year 2024 earnings on Feb. 19, after market close. In the last reported quarter, BMRN’s earnings beat estimates by 16.67%.The Zacks Consensus Estimate for sales and earnings is pegged at $711.9 million and 73 cents per share, respectively, indicating a significant rise from the year-ago levels.See the Zacks Earnings Calendar to stay ahead of market-making news.Factors Shaping BMRN’s Upcoming ResultsThough BioMarin’s portfolio comp ...

The upcoming report from BioMarin Pharmaceutical (BMRN) is expected to reveal quarterly earnings of $0.73 per share, indicating an increase of 49% compared to the year-ago period. Analysts forecast revenues of $711.93 million, representing an increase of 10.2% year over year.Over the last 30 days, there has been a downward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts o ...

Core Viewpoint - The analysis compares BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY) to determine which stock is more attractive to value investors [1]. Group 1: Zacks Rank and Earnings Outlook - BMRN has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while CSLLY has a Zacks Rank of 5 (Strong Sell) [3]. - The Zacks Rank system emphasizes companies with positive earnings estimate revisions, suggesting that BMRN's earnings outlook is improving more significantly than CSLLY's [3][7]. Group 2: Valuation Metrics - BMRN has a forward P/E ratio of 15.85, compared to CSLLY's forward P/E of 22.76, indicating that BMRN may be undervalued relative to CSLLY [5]. - The PEG ratio for BMRN is 0.44, while CSLLY's PEG ratio is 1.47, further suggesting that BMRN is a more attractive value option [5]. - BMRN's P/B ratio is 2.24, significantly lower than CSLLY's P/B of 4.03, reinforcing the notion that BMRN is undervalued [6]. - These metrics contribute to BMRN's Value grade of B and CSLLY's Value grade of F, highlighting BMRN's superior valuation [6].

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth S ...

SAN RAFAEL, Calif., Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. ET to discuss fourth quarter and full-year 2024 financial results and provide a general business update.Dial-in Number U.S. / Canada Dial-in Number: 800-715-9871International Dial-in Number: 646-307-1963Conference Call ID: 1878833U.S. / Canada ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estim ...

This is my third BioMarin (NASDAQ: BMRN ) article following 07/2024's "BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal" (" Big Reveal "). In the interim BioMarin has dropped >26%. Whenever a company loses that much that fast a fundamental question arises; is itWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share m ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the trad ...

The macroenvironment in 2025 looks grim as signs of a slowdown in the economy set in. The biotech industry experienced a choppy ride in 2024, and the same is likely in store in 2025. Given the continuous need for innovative medical treatments, irrespective of the state of the economy, the biotech industry will continue to grab investors’ interest despite the inherent volatility and uncertain macroeconomic environment.M&A activity is likely to accelerate in 2025 with a change in administration and expected d ...